A roadblock to personalized cancer care?

Experts call for more support for tumor biomarker tests; fixing a vicious cycle will lead to tests that better predict treatment success

2013-08-01

(Press-News.org) ANN ARBOR, Mich. — There's a major roadblock to creating personalized cancer care.

Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.

The problem, according to a new commentary paper, is that, unlike drugs or other therapies, cancer biomarker tests are undervalued by doctors and patients. The authors say that inconsistent regulatory rules, inadequate payment and underfunded tumor biomarker research has left us in a vicious cycle that prevents development and testing of reliable biomarker tests that could be used to personalize clinical care of patients with cancer.

"Right now biomarkers are not valued nearly to the extent that we see with therapeutics. But if a tumor biomarker test is being used to decide whether a patient should receive a certain treatment, then it is as critical for patient care as a therapeutic agent. A bad test is as dangerous as a bad drug," says Daniel F. Hayes, M.D., clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center.

Hayes led a blue-ribbon panel of experts from universities, corporations, insurance and advocacy organizations to outline the issues in a commentary published today in Science Translational Medicine.

Tumor biomarker tests look at the genetic or molecular make-up of a tumor to determine whether the cancer is likely to progress, and if so, if it is likely to respond to treatment. If the test is good, it can help doctors decide when a patient can safely skip further therapy, or it can be used to direct which drug might be most likely to help. The result: "personalized medicine," which means patients get treatments that benefit them specifically and they avoid treatments – including their costs and side effects – that are not likely to make a difference for them.

The regulatory process, the research funding, the reimbursement, even the standards for journal publications for tumor biomarker tests are all meager compared to the robust support for drug development, the authors say.

This creates a vicious cycle in which researchers and drug companies don't invest in tumor biomarker research, tests are not fully evaluated in clinical trials, and tests with uncertain value in terms of predicting the success of treatment are published. This in turn means that few of these tests are included in evidence-based care guidelines, leaving health care professionals unsure of whether or how to use the test, and third-party payers unsure of how much to pay for them.

The authors outline five recommendations and suggest that all five must be addressed to break the vicious cycle:

Reform regulatory review of tumor biomarker tests Increase reimbursement for tumor biomarker tests that are proven to help determine which therapies will or are working Increase investment for tumor biomarker research so it's comparable to new drug research Increase the rigor for peer review of tumor biomarker publications Include only proven biomarker tests in evidence-based care guidelines

"These recommendations are not about creating more regulation; they are about creating an even playing field that allows tumor biomarker tests to be developed and proven clinically relevant. We want to stimulate innovation yet hold investigators and clinicians to the highest scientific standards – as we now do for therapeutics," Hayes says. "We need to change the way we value tumor biomarkers in this country."

INFORMATION:

Additional authors: Jeff Allen, Friends of Cancer Research; Carolyn Compton, Critical Path Institute; Gary Gustavsen, Health Advances; Debra G.B. Leonard, University of Vermont College of Medicine; Robert McCormack, Veridex; Lee Newcomer, United Health Care; Kristin Potheir, Health Advances; David Ransohoff, University of North Carolina School of Medicine; Richard L. Schilsky, American Society of Clinical Oncology; Ellen Sigal, Friends of Cancer Research; Sheila E. Taube, ST-Consulting; Sean R. Tunis, Center for Medical Technology Policy

Disclosure: Hayes is a consultant for Oncimmune LLC, Inbiomotion, and Biomarker Strategies and has received research funding from Novartis, Veridex (Johnson & Johnson), and Janssen R&D, LLC (Johnson & Johnson). He is a co-inventor on a patent for a method for predicting progression-free and overall survival in metastatic breast cancer patients using circulating tumor cells; and has applied for patents for a test for diagnosis and treatment of breast cancer and for circulating tumor cell capturing techniques and devices.

Reference: Science Translational Medicine, Vol. 5, No. 196, July 31, 2013

Resources:

U-M Cancer AnswerLine, 800-865-1125

U-M Comprehensive Cancer Center, http://www.mcancer.org Clinical trials at U-M, http://www.mcancer.org/clinicaltrials

ELSE PRESS RELEASES FROM THIS DATE:

When prescribing antibiotics, doctors most often choose strongest types of drugs

2013-08-01

(SALT LAKE CITY)—When U.S. physicians prescribe antibiotics, more than 60 percent of the time they choose some of the strongest types of antibiotics, referred to as "broad spectrum," which are capable of killing multiple kinds of bacteria, University of Utah researchers show in a new study. Unfortunately, in more than 25 percent of such prescriptions are useless because the infection stems from a virus, which cannot be treated with antibiotics. This overuse of antibiotics has a number of downsides, including that these types of drugs kill more of the "good" bacteria ...

Existing cropland could feed 4 billion more

2013-08-01

The world's croplands could feed 4 billion more people than they do now just by shifting from producing animal feed and biofuels to producing exclusively food for human consumption, according to new research from the Institute on the Environment at the University of Minnesota. Even a smaller, partial shift from crop-intensive livestock such as feedlot beef to food animals such as chicken or pork could increase agricultural efficiency and provide food for millions, the study says. "We essentially have uncovered an astoundingly abundant supply of food for a hungry world, ...

Light that moves and molds gels

2013-08-01

PITTSBURGH—Some animals—like the octopus and cuttlefish—transform their shape based on environment, fending off attackers or threats in the wild. For decades, researchers have worked toward mimicking similar biological responses in non-living organisms, as it would have significant implications in the medical arena. Now, researchers at the University of Pittsburgh have demonstrated such a biomimetic response using hydrogels—a material that constitutes most contact lenses and microfluidic or fluid-controlled technologies. Their study, published in Advanced Functional ...

When it comes to skin cancer, pictures are worth 1,000 words

2013-08-01

WATERLOO, Ont. (Thursday, August 1, 2013) – Seeing pictures of skin cancer motivates people to regularly check their own moles, according to a new research paper from the School of Public Health and Health Systems at the University of Waterloo. The paper, published in the Journal of the American Academy of Dermatology, found that visual images of skin cancer are most effective in prompting skin self-examinations. "Visual images capture our attention and are persuasive. They also help us to learn and remember," said Professor Laurie Hoffman-Goetz, of the Faculty of Applied ...

Removing a protein enhances defense against bacteria in CGD mice

2013-08-01

Deletion of a protein in white blood cells improves their ability to fight the bacteria staphylococcus aureus and possibly other infections in mice with chronic granulomatous disease (CGD), according to a National Institutes of Health study. CGD, a genetic disorder also found in people, is marked by recurrent, life-threatening infections. The study's findings appear online in The Journal of Clinical Investigation. A team of researchers from NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) compared three groups: CGD-afflicted mice with the ...

Anemia linked to increased risk of dementia

2013-08-01

MINNEAPOLIS – Anemia, or low levels of red blood cells, may increase the risk of dementia, according to a study published in the July 31, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. "Anemia is common in the elderly and occurs in up to 23 percent of adults ages 65 and older," said study author Kristine Yaffe, MD, with the University of California – San Francisco and a member of the American Academy of Neurology. "The condition has also been linked in studies to an increased risk of early death." For the study, 2,552 older ...

Citizen scientists rival experts in analyzing land-cover data

2013-08-01

Over the past 5 years, IIASA researchers on the Geo-Wiki project have been leading a team of citizen scientists who examine satellite data to categorize land cover or identify places where people live and farm. These data have led to several publications published in peer-reviewed journals. "One question we always get is whether the analysis from laypeople is as good as that from experts. Can we rely on non-experts to provide accurate data analysis?" says IIASA researcher Linda See, who led the study published in the journal PLOS ONE. The researchers compared 53,000 ...

1 in 3 US youths report being victims of dating violence

2013-08-01

HONOLULU – About one in three American youths age 14-20 say they've been of victims of dating violence and almost one in three acknowledge they've committed violence toward a date, according to new research presented at the American Psychological Association's 121st Annual Convention. "These rates of adolescent dating violence are alarming and suggest that dating violence is simply too common among our youth," said Michele Ybarra, PhD, MPH, with the Center for Innovative Public Health Research, based in San Clemente, Calif. Researchers analyzed information collected ...

Rituximab therapy effective for ANCA-associated vasculitis

2013-08-01

WA, Seattle -- In an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxan, Genentech, Inc.) is as effective as the current standard of care regimen of drugs for remission induction and maintenance in patients with ANCA-associated Vasculitis (AAV). AAV is an autoimmune disease marked by the presence of antibodies that attack neutrophils and cause inflammation of the blood vessels, leading to organ damage and sometimes death. The standard of care ...

ITN achieves scientific manuscript first -- provides open, interactive access to clinical trial data

2013-08-01

WA, Seattle (July 26, 2013) – In an article reporting the 18-month results of the ITN's RAVE clinical trial, published August 1st in the New England Journal of Medicine, the ITN is providing unfettered access to the underlying clinical data and analysis code via the new clinical trials research portal, ITN TrialShare. TrialShare is a significant advance in data sharing and transparency, allowing for collaborative hypothesis generation and specimen sharing between the ITN and the broader scientific community. TrialShare gives researchers the ability to access raw study data, ...

A roadblock to personalized cancer care?

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: